Clinical trial
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients…
NCT00005032 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00005032 |
|---|---|
| Title | Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer |
| Official title | A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, paclitaxel |
| Enrollment | 12 |
| Start date | Apr 1, 2000 |
| Primary completion | Jan 1, 2001 |
| Completion | Sep 1, 2001 |
| First posted | Jun 4, 2004 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: